Plasmapheresis Shows No Anti-Aging Benefits in First Human Epigenetic Clock Study
Czech researchers find plasma removal may actually accelerate biological aging markers despite removing inflammatory factors.
Summary
A Czech clinical trial tested whether plasmapheresis (plasma removal) could slow aging by eliminating harmful circulating factors. Forty-one healthy adults aged 40-60 underwent either 4 or 8 plasma removal sessions over 18 weeks. While the procedure successfully reduced cholesterol, triglycerides, and inflammatory markers, epigenetic clock measurements showed no rejuvenation. Instead, participants showed increases in DNAmGrimAge and other aging biomarkers, suggesting the intervention may have accelerated biological aging rather than slowing it.
Detailed Summary
This groundbreaking study represents the first human clinical trial examining plasmapheresis effects on epigenetic aging markers. The research addresses a critical question in longevity science: whether removing potentially harmful factors from blood plasma can slow biological aging.
Researchers at Charles University conducted a crossover trial with 41 healthy blood donors aged 40-60. Participants underwent either 4 or 8 plasmapheresis sessions over 18 weeks using standard blood donation protocols. The team measured comprehensive biomarkers including multiple epigenetic clocks (DNAmAge, DNAmGrimAge, Hannum clock, Dunedin Pace of Aging) alongside biochemical and hematological parameters.
The intervention successfully altered circulating factors associated with aging. Participants showed significant reductions in total cholesterol, triglycerides, apolipoprotein A, and total proteins. These changes align with the theoretical benefits of removing pro-aging molecules from circulation, similar to promising results seen in animal studies.
However, the epigenetic aging results were concerning. Rather than showing rejuvenation, participants demonstrated increases in DNAmGrimAge (a predictor of lifespan and healthspan), the Hannum clock, and the Dunedin Pace of Aging. These findings suggest the intervention may have accelerated biological aging processes despite removing inflammatory factors.
The study's implications extend beyond plasmapheresis to broader anti-aging strategies. While removing harmful circulating factors remains theoretically sound, this research highlights the complexity of aging biology and the potential for unintended consequences. The results challenge assumptions about plasma-based interventions and underscore the need for rigorous human testing of anti-aging therapies before clinical implementation.
Key Findings
- Plasmapheresis increased DNAmGrimAge and other epigenetic aging markers despite removing pro-aging factors
- Significant reductions in cholesterol, triglycerides, and inflammatory proteins occurred within 18 weeks
- No epigenetic rejuvenation was observed across multiple aging clock measurements
- Red cell distribution width and mean corpuscular hemoglobin concentration increased
- First human study to examine plasmapheresis effects on epigenetic aging markers
Methodology
Crossover trial with 41 healthy adults aged 40-60 undergoing 4 or 8 plasmapheresis sessions over 18 weeks. Multiple epigenetic clocks measured alongside comprehensive biochemical and hematological parameters using standard blood donation protocols.
Study Limitations
Relatively short 18-week duration may not capture long-term effects. Small sample size and first-time blood donor population may limit generalizability. Standard donation protocols weren't optimized for anti-aging outcomes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.